Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Lineage Commitment01:21

Lineage Commitment

3.0K
Commitment is the  process whereby stem cells:
3.0K
Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

972
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
972
Disorders of Leukocytes01:27

Disorders of Leukocytes

914
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
914
Production of Formed Elements01:34

Production of Formed Elements

1.3K
Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polyclonal evolution of lymphoproliferative disorders in XLP1.

Journal of human immunity·2026
Same author

BCL11B enhancer hijacking by t(14;16)(q32;q24) translocation defines a novel high-risk subtype of T-ALL.

Blood·2026
Same author

Functional impact of a deep intronic variant in the RPS19 gene detected in a case of Diamond-Blackfan anemia syndrome.

Haematologica·2026
Same author

Biological Features of KLC2 Mutations in Chronic Myeloid Leukemia and Their Contribution to Inducing Drug Resistance.

Oncology research·2026
Same author

Comprehensive molecular and functional analysis of NUTM1-rearranged leukemia.

Blood·2025
Same author

Somatic mutations and clonal evolution in normal tissues and cancer development.

Experimental & molecular medicine·2025

Related Experiment Video

Updated: Jun 14, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.6K

[Clonal evolution in myeloproliferative neoplasms].

Kenichi Yoshida1

  • 1Division of Cancer Evolution, National Cancer Center Research Institute.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|September 4, 2024
PubMed
Summary
This summary is machine-generated.

Recent advances reveal driver mutations in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). These mutations, including epigenetic regulators, can arise early in life and influence disease progression.

Keywords:
Clonal evolutionDriver mutationsMPN

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.5K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.8K

Related Experiment Videos

Last Updated: Jun 14, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.6K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.5K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.8K

Area of Science:

  • Hematology
  • Genetics
  • Oncology

Background:

  • Sequencing technologies have advanced the understanding of driver gene mutations in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs).
  • Beyond JAK2, MPL, and CALR mutations, epigenetic regulators and RNA splicing factors are implicated in MPN pathogenesis.
  • Clonal hematopoiesis, the expansion of hematopoietic cells with driver mutations, is observed in healthy individuals, particularly the elderly.

Purpose of the Study:

  • To review recent findings on clonal evolution in MPNs.
  • To elucidate the role of driver mutations in MPN development and progression.

Main Methods:

  • Review of recent scientific literature on MPNs, driver mutations, and clonal evolution.
  • Analysis of sequencing data and genetic studies related to MPN pathogenesis.

Main Results:

  • Identification of somatic mutations in epigenetic regulators and RNA splicing factors beyond the main MPN drivers.
  • Association of these mutations with transformation to myelofibrosis and acute myeloid leukemia.
  • Evidence suggesting that initial driver mutations in MPN patients, such as JAK2 and DNMT3A, can be acquired prenatally or in childhood.

Conclusions:

  • Driver mutations play a critical role in the clonal evolution of MPNs.
  • Understanding the timing and spectrum of driver mutations is crucial for comprehending MPN pathogenesis and developing targeted therapies.